Last updated on October 2018

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir Dasabuvir Ribavirin in Patients With Chronic Hepatitis C in Colombia


Brief description of study

The interferon-free combination regimen of Paritaprevir/r - Ombitasvir with or without Dasabuvir (ABBVIE REGIMEN) ± Ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions. This observational study is the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in Israel in a clinical practice patient population.

Clinical Study Identifier: NCT02851069

Contact Investigators or Research Sites near you

Start Over

Angela Paola Duarte, MS

Fundacion Santa Fe de Bogota /ID# 155736
Bogota, Colombia

Angela Paola Duarte, MS

Fundacion Cardioinfantil /ID# 155724
Bogota, Colombia

Angela Paola Duarte, MS

Medplus Medicia Prepagada /ID# 163985
Bogota, Colombia

Angela Paola Duarte, MS

Cic Cali /Id# 163986
Cali, Colombia

Angela Paola Duarte, MS

Centro Medico Imbanaco /ID# 163660
Cali, Colombia

Angela Paola Duarte, MS

Fundacion Valle Del Lili /ID# 155723
Cali, Colombia

Angela Paola Duarte, MS

Pharos Centro de Estudios Clinicos /ID# 161709
Cartagena, Colombia

Angela Paola Duarte, MS

Ips Medicos Internistas Del Caldas /Id# 163987
Manizales, Colombia

Angela Paola Duarte, MS

Fundacion Hospitalaria San Vincente de Paul /ID# 167437
Medellin, Colombia

Angela Paola Duarte, MS

IPS Universitaria /ID# 155725
Medellin, Colombia

Angela Paola Duarte, MS

Hospital Pablo Tobon Uribe /ID# 155722
Medellin, Colombia